Dialysis Access Treatment Devices – Market Insights – United States

The US dialysis access treatment device market will grow at a moderate rate due to the increasing adoption of innovative products, positive clinical data, and rising ASPs of specific devices like AVGs.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for dialysis access treatment devices in the US from 2019 through 2034.

Medtronic’s exit from the percutaneous AVF market may limit the segment’s growth potential.

What is the expected impact of Medtronic’s withdrawal on the percutaneous AVF market?

What are the implications of this exit on patient access to less invasive dialysis access creation options in the US?

To what extent does the persistent preference for surgical AVFs in the US continue to restrict the uptake of alternative access creation technologies?

Favorable clinical trial results and the approval of new devices are changing the market and competitive landscape.

What has been the impact of recent clinical trial results on the market growth and competitive landscapes in the percutaneous AVF catheter and DCB segments?

What is the competitive outlook in the percutaneous thrombectomy segment, considering the current competitive landscape and the recent launch of a new device?

The anticipated launch of devices featuring incremental safety, effectiveness, and ease-of-use enhancements will impact the dialysis access treatment device market.

Which procedure groups are expected to see new devices enter the market?

How will surgical AVF procedures and use of AVGs and dialysis catheters be affected by the exit of Medtronic’s percutaneous AVF catheter?

What other emerging technologies are on the horizon that will bring further competition to the dialysis access creation market?